SMA is a genetic disorder that causes a chronic deficiency in the production of the survival motor neuron (SMN) protein.
Invitrogen scientists will use the ProtoArray technology to screen approximately 3,000 human proteins and 5,000 yeast proteins as potential targets for SMA therapeutic intervention. The work builds upon the identification of compounds that up-regulate SMN levels in an FSMA-sponsored program at DeCode Genetics, FSMA said.
"We hope that the discovery and characterization of critical protein targets and their associated pathways will lead to new drug discovery avenues and ultimately to novel therapeutic approaches to treat SMA," said Jill Jarecki, research director of FSMA, in a statement.
The organizations said that the initial target identification stage will be followed by "further collaborative work to validate the targets and develop new compound screening assays."
Financial terms of the collaboration were not disclosed.